Stocks
Coherus Oncology, Inc.CHRS
NASDAQHealthcareBiotechnology$1.63-3.55%
A biotechnology company focused on developing and commercializing biosimilars and immuno-oncology therapies. Its portfolio has included biosimilar versions of major biologic drugs and newer cancer treatments such as the PD-1 inhibitor toripalimab, with revenue historically driven by its pegfilgrasti...
Market Cap: $190.9M52W Range: $0.71 – $2.62
Congressional Interest in Coherus Oncology, Inc. (CHRS)
1 member of Congress has disclosed 1 trade in Coherus Oncology, Inc. (CHRS), a Healthcare company. The buy/sell breakdown shows 0 purchases versus 1 sale, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
1
Unique Politicians
1
Buys
0
Sells
1
Who in Congress Is Trading CHRS?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2023-01-23 | Shri Thanedar | sell | $15K – $50K |